Jasper Therapeutics News

Buy Rating Affirmed: Jasper Therapeutics' Briquilimab Shows Promising Outlook in Chronic Urticaria Treatment Market

TipRanksApr 24 22:55 ET

Jasper Therapeutics Analyst Ratings

BenzingaApr 3 07:32 ET

Jasper Therapeutics Analyst Ratings

BenzingaMar 28 04:35 ET

Buy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria Treatment

TipRanksMar 20 09:05 ET

Analysts' Top Healthcare Picks: Jasper Therapeutics (JSPR), Alphatec Holdings (ATEC)

TipRanksMar 20 09:00 ET

Jasper Therapeutics Analyst Ratings

BenzingaMar 18 08:33 ET

Buy Rating for Jasper Therapeutics: Promising Prospects for Briquilimab in Treating Chronic Urticaria

TipRanksMar 18 05:45 ET

Jasper Therapeutics Analyst Ratings

BenzingaMar 7 08:01 ET

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biomea Fusion (BMEA) and Jasper Therapeutics (JSPR)

TipRanksMar 7 07:41 ET

Buy Rating Affirmed: Jasper Therapeutics' Progress and Potential in Addressing Unmet Needs in Chronic Urticaria Treatment

TipRanksMar 4 13:15 ET

Oppenheimer Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)

TipRanksFeb 27 07:48 ET

Buy Rating on Jasper Therapeutics Highlighting Briquilimab's Potential in Chronic Urticaria Treatment

TipRanksFeb 26 14:25 ET

Buy Rating for Jasper Therapeutics: Promising Developments in CSU Treatment Pipeline and Anticipated Clinical Milestones

TipRanksFeb 21 09:45 ET

Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics, Maintains $6 Price Target

BenzingaOct 12, 2023 11:50 ET

Jasper Therapeutics Analyst Ratings

BenzingaOct 12, 2023 11:46 ET

Credit Suisse Reiterates Outperform on Jasper Therapeutics, Maintains $4 Price Target

BenzingaAug 14, 2023 08:08 ET

Jasper Therapeutics Analyst Ratings

BenzingaAug 14, 2023 08:08 ET

Jasper Therapeutics Analyst Ratings

BenzingaAug 11, 2023 10:26 ET

EF Hutton Sticks to Its Buy Rating for Jasper Therapeutics (JSPR)

TipRanksJun 12, 2023 08:25 ET

EF Hutton Reiterates Buy on Jasper Therapeutics, Maintains $6.85 Price Target

BenzingaJun 12, 2023 07:15 ET